Microglial phenotype and phagocytic activity are deregulated in Parkinson's disease (PD). PPARγ agonists are neuroprotective in experimental PD, but their role in regulating microglial phenotype and phagocytosis has been poorly investigated. We addressed it by using the PPARγ agonist MDG548.
Introduction
A chronic and deregulated glial response contributes to the progression and spreading of neurodegeneration in Parkinson's disease (PD) (Joers et al., 2017) . Specifically, an imbalance in pro-inflammatory/anti-inflammatory microglia is regarded as a main pathological contributor to chronic neuroinflammation and neurodegeneration in PD and targeting cytokine production by microglia has been suggested as a promising disease-modifying strategy in PD (SanchezGuajardo et al., 2010; Tang and Le, 2016) . Moreover, sporadic studies have reported an abnormal phagocytosis by microglia in PD, although whether it is up-regulated or down-regulated in the pathology is still a matter of debate (Salman et al., 1999; Gardai et al., 2013) . Measurement of CD68 has been proposed as a marker of phagocytosis, and morphological analysis of microglia pointed to an increased phagocytic activity in PD (Barcia et al., 2013; Croisier et al., 2005; Depboylu et al., 2012; Doorn et al., 2014; Sanchez-Guajardo et al., 2010; Theodore et al., 2008) , while functional studies with latex beads indicate a defect in the phagocytic function of microglia or other immune cells (Salman et al., 1999; Gardai et al., 2013) . Phagocytosis is a beneficial event, which has been traditionally associated with an anti-inflammatory profile of microglia, whereas this may not be the case in PD, where microglia may acquire mixed pro-inflammatory and antiinflammatory phenotypes. Therefore, whether phagocytosis is a beneficial or detrimental event in PD is still debated, and how it is modified by neuroprotective drugs has not been investigated (Nolan et al., 2013; Peña-Altamira et al., 2015; Plaza-Zabala et al., 2017) .
A finely regulated production of pro-inflammatory and anti-inflammatory cytokines, growth factors and toxic molecules, such as free radicals and NO, shapes microglia phenotype into either pro-inflammatory or anti-inflammatory. Moreover, a number of membrane markers characterize microglial phenotype and function, among which mannose receptor C type 1 (MRC1) and β-N-acetylhexosaminidase/ chitinase-like 3 (Ym1) have been associated with antiinflammatory phenotypes (Subramaniam and Federoff, 2017) . MRC1 is a pattern recognition membrane receptor involved in innate and adaptive immunity, specifically in microglial phagocytosis. Expression of this receptor is controlled by cytokines, being down-regulated by proinflammatory and up-regulated by anti-inflammatory cytokines (Zimmer et al., 2003) . Inside the cell, CD68 is mainly located on lysosomes, belonging to the family of lysosomal glycoproteins, and its rapid recirculation from endosomes and lysosomes to the plasma membrane may improve the function of the phagocytic machinery, although the role and involvement of this protein in phagocytosis has been recently questioned and remains to be determined (Song et al., 2011; Chistiakov et al., 2017) . Increased CD68 expression has been related to dopamine neuron degeneration in PD (Croisier et al., 2005; Sanchez-Guajardo et al., 2010) . Finally, Beclin-1 is an autophagy-regulating protein recently shown to play a critical role in microglial phagocytosis of β-amyloid (Lucin et al., 2013) . Beclin-1 expression is reduced in microglia of Alzheimer's disease patients, and lack or reduced levels of Beclin-1 impair microglia phagocytosis in a model of Alzheimer's disease (Lucin et al., 2013) . Moreover, Beclin-1 levels can be induced by the exposure to phagocytosispromoting factors in macrophages (Wu et al., 2016) .
The nuclear receptor PPARγ is a promising target for a number of neurodegenerative diseases with a relevant neuroinflammatory component, including PD (Nolan et al., 2013; Skerrett et al., 2014) . The thiazolidinediones (TZDs) pioglitazone and rosiglitazone, and the more recently characterized PPARγ agonist MDG548 effectively prevent or arrest nigrostriatal degeneration in vivo in the Parkinsonian rodent and monkey models and counteract the neuroinflammatory response in terms of inflammatory cytokine production (Swanson et al., 2011; Carta, 2013; Pisanu et al., 2014; Lecca et al., 2015) . MDG548 was identified as a PPARγ agonist with a thiobarbituric acid structure, displaying a twofold higher PPARγ affinity and increased BBB permeability, compared with the TZDs (Nevin et al., 2012) . PPARγ function has been extensively characterized in peripheral immune cells, where it mediates many immunomodulatory effects in macrophages, monocytes and granulocytes (Reddy, 2008) . Hence, PPARγ acts as a master regulator of macrophage phenotype in physiological as well as pathological conditions, by driving the acquisition of an anti-inflammatory, or alternative activation state (Bouhlel et al., 2007; Croasdell et al., 2015; Glass and Saijo, 2010; Odegaard and Chawla, 2011; Penas et al., 2013; Varga et al., 2011) . Moreover, PPARγ governs the promotion of phagocytosis and tissue repair by macrophages (Nagy et al., 2012) . Whether similar roles are fulfilled by PPARγ expressed in microglia in neurological disorders has recently started to be elucidated in vitro and in vivo models (Ajmone-Cat et al., 2012; Pisanu et al., 2014; Savage et al., 2015; Zhao et al., 2015; Flores et al., 2016; Pinto et al., 2016) . In PD, studies suggest that regulation of genes involved in the inflammatory response may represent one mechanism of PPARγ-mediated neuroprotection, but modulation of microglia phagocytosis has not been investigated.
The specific aim of the present study was to investigate the effect of the PPARγ agonist MDG548 on phagocytosis and microglia phenotype in PD models, together with its disease-modifying potential in vivo. Given the complexity of in vivo systems, and the broad distribution of PPARγ in different cell types, including immune cells, astrocytes and neurons, assessing the direct effects of PPARγ agonists on a selective cell type in vivo is questionable. For this reason, we first tested MDG548 on unstimulated and LPS-stimulated microglia in an in vitro system made of pure MMGT12 microglial cells that are comparable with primary microglial cells with respect to several microglial markers (Briers et al., 1994; Michelucci et al., 2009; Heurtaux et al., 2010) . In this model, we measured the phagocytosis of fluorescent latex beads or necrotic dopaminergic neuroblastoma cells and cell debris, the levels of CD68 and Beclin-1 and the production of MRC1, pro-inflammatory and anti-inflammatory cytokines and inducible NOS (iNOS). Thereafter, we tested MDG548 in an in vivo model of PD obtained by the chronic administration of MPTP plus probenecid (MPTPp), which reproduces the progressive nature of dopaminergic degeneration and inflammatory responses of PD. In this model, we investigated the effect of MDG548 on dopaminergic cell loss and motor impairment and on MRC1 levels and cytokine production by microglia.
Methods

MMGT12 microglial cells and treatments
The murine microglial cell line MMGT12 was used and was a generous gift from T. Heurtaux and A. Michelucci (Luxembourg) . Cells were cultured in DF culture medium comprising DMEM/F12 (1:1, vol/vol), supplemented with 10% FBS without antibiotics, grown in humidified atmosphere of 5% CO2 at 37°C, harvested and seeded twice a week. For ELISA and immunocytochemistry, MMGT12 cells were seeded into 12-well plates previously filled with 18 mm coverslips. Cell density was 15 × 10 3 per well at the time of seeding to ensure 70% confluence on coverslips after 3 days in vitro (DIV), when most cells presented a common morphological appearance. Three days after plating, cells were treated with LPS or MDG548 or LPS plus MDG548 added either at the same time (concurrent, c) or after 2 h (sequential, s) according to Table 1 .
Phagocytosis of latex microspheres
The whole experiment was repeated three times (each on a different day), with an n = 3 of independent samples (3 separate plates) in each experimental group. We planned to perform three separate experiments with three independent samples for each experimental group since a higher n would have implied longer and inhomogeneous processing time, compromising the results. Upon verification of the homogeneity of the data, results from three experiments were collected, and statistical analysis was performed with a final n of nine samples for each experimental group. MMGT12 cells were seeded on 24-well plates (5 × 10 4 cells per well) and incubated in DF culture medium in absence or presence of drugs, according to Table 1 . Control wells were treated with the corresponding vehicles. Twenty-four hours later, medium was temporarily removed. Cells were washed in PBS, trypsinized in 0.05% trypsin for 3 min and re-plated in the same wells, using the same medium for 1 h. Fluoresbrite Carboxy YG 6.0 μm Microspheres (cat#18141; Polysciences Inc., Warrington, PA, USA) were resuspended in PBS with 5.5 mM glucose, 1.5 mM magnesium and 1 mM calcium and pre-opsonized by addition of 50% FBS and incubation for 30 min in 5% CO 2 at 37°C. The 12 × 10 6 preopsonized microspheres were resuspended in 12 mL of DF culture medium without FBS and distributed on cells (about 10 beads per cell) and incubated for 2 h. Cells were washed with PBS, trypsinized for 5 min and collected with 0.5 mL of culture medium in conical tubes (for flow cytometry), centrifuged at 290× g for 5 min, PBS washed and centrifuged again for 3 min. Cell pellet was suspended in 0.3 mL PBS containing 1% FBS. Cells were acquired in the green channel (502 nm) by FACSCanto II (BD Biosciences, Erenbodgem, Belgium). The percentage of green cells was determined on the single-cell population by BD FACSDiva software.
SH-SY5Y cells phagocytosis assay
For the technical reasons reported above, this experiment was carried out twice (each on a different day) with three independent samples (3 plates) each time, and thus, the final n of independent samples was 6 for each experimental group. 
Western blotting analysis
MMGT12 cells were seeded on six-well plates at density 4 × 10 4 cells per well. After 3 days, cells were treated according to Table 1 . Twenty-four hours later, cells were lysed and processed for SDS-PAGE and Western blotting analysis according to a previously published procedure (Janda et al., 2015) . The experiment was repeated five times, and the samples were loaded on at least two different gels each time, and whenever possible, the mean OD signal was analysed and calculated for each experiment. Rabbit anti-Beclin (MBL, cat#PD017, 1:2000) and rabbit anti-GAPDH (cat#sc87752, 1:500; Santa Cruz Biotech. Inc, Santa Cruz, Dallas, TX, USA) were used as primary antibodies. HRP-conjugated goat anti-rabbit (cat#31460, 1:5000; Thermo Scientific) was used as a secondary antibody. Blots were developed with the enhanced chemiluminescence method, using ImmunoStar TM (cat# 170-5070; Bio-Rad Lab. Inc.) and digitally acquired using a ChemiDoc XRS imaging system (Bio-Rad Lab. Inc.).
In vivo model of PD in mice
All animal care and experimental procedures complied with the Directive 63/2010/EU on the protection of animals used for scientific purposes and were approved by the Ethics Committee of the University of Cagliari. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . Three-month-old male C57BL/6J mice were purchased from Charles River (Calco, Italy) and randomized into six experimental groups (total n = 30). Animals were housed five per cage, in plastic cages with conventional bedding, in the animal facility of the Department of Biomedical Sciences, under controlled environmental conditions, with a 12:12 h light/dark cycle, 23-24°C, food and water ad libitum and the proper enrichment.
The control group of mice (n = 5) received saline as a vehicle. The remaining mice were randomly allocated into additional groups (n = 5 per group) to receive daily vehicle (30% DMSO, 10% PEG in water), plus 3 (MPTP3), 7 (MPTP7) and 10 (MPTP10) doses of MPTP (25 In a separate experiment, 15 mice (n = 5 per group: vehicle, MPTP10 and MPTP + MDG548) were anaesthetized and immediately killed without PFA perfusion, and their brains were used for RT-PCR experiments.
Immunocytochemistry and immunohistochemistry
Cells plated as described in MMGT12 microglial cells and treatments section were incubated in a medium containing 5% FBS plus factors added according to Coronal sections from mouse substantia nigra pars compacta (SNc) (40 μm thick) were vibratome cut and incubated with primary antibodies against tyrosine hydroxylase (TH; monoclonal anti-TH 1:1000; Sigma-Aldrich), CD11b (monoclonal anti-CD11b 1:1000; Serotec, Oxford, UK), TNF-α (TNF-α polyclonal rabbit anti-TNF-α 1:800; Abbiotec), IL-1β (IL-1β polyclonal rabbit anti-IL-1β 1:200; Abbiotec), MRC1 (polyclonal anti-MRC1 1:500; Santa Cruz Biotech. Inc) and TGF-β (TGF-β polyclonal rabbit anti TGF-1β 1:200; Abbiotec) and the secondary antibodies, except for TH where the classic avidin-peroxidase complex (ABC; Vector Labs. Ltd) protocol was applied using 3,30-diaminobenzidine (Sigma-Aldrich) as a chromogen. A three-step detection was used to increase signal of cytokines and MRC1 by biotin-conjugated IgG plus streptavidin-fluorescein (1:200; Vector Labs. Ltd).
Stereological counting of TH immunoreactivity
All immunohistochemical reactions were analysed by an operator blinded to experimental groups and different from the experimenter that performed the behavioural tests and histology. TH-immunoreactive and Nissl-stained neurons were counted bilaterally in the SNc as previously described (Lecca et al., 2015) . A dedicated software was used (Stereologer; System Planning and Analysis, Inc., Alexandria, VA, USA) linked to a motorized stage on the BX-60 Olympus light microscope (Olympus Optical, GmbH, Hamburg, Germany). The total number of TH-stained or Nissl-stained cells was estimated by means of Optical Fractionator method, which combines the optical dissector with the fractionator sampling scheme, giving a direct estimation of the number of three-dimensional objects unbiased by shape, size and orientation (Mouton et al., 2002) . A systematic random sampling of cells within the area of interest was achieved by 'Stereologer' program. Equidistant counting frames (frame area = 50 μm 2 ) were obtained. Sampling fraction was delimited at low power, and cells were sampled with a ×40 oil immersion objective through a defined depth with a 2 μm guard zone. The coefficient of error for each estimation and animal ranged from 0.05 to 0.1.
CD11b analysis
CD11b-positive microglia were identified at ×100/1.25 oil magnification. For each animal, six fields of SNc were captured from both the left and the right SNc and analysed. For each microglial cell, the body and primary processes were outlined. The total area occupied by CD11b immunoreactivity (IR) and the mean area per cell was measured using NIH software ImageJ 1.47v (NIH, Bethesda, MD, USA).
Confocal analysis
Quantitative analysis for CD68 colocalization with PPARγ in MMGT12 cells, TNF-α, IL-1β, MRC1 and IL-10 colocalization with CD11b in vivo was performed using a Leica 4D confocal laser scanning microscope, equipped with an argon-krypton laser (Carta et al., 2011) . Images were digitized 24 h after the immunofluorescence procedure. Surface rendering, maximum intensity, colocalization and simulated fluorescence process algorithms were used (ImageJ 1.48q and Imaris 7.0). Volume of colocalized elements was determined as follows: for each dataset (40-60 images), a colocalization channel was automatically composed by Imaris 7.3. In the resulting stacks, four regions of interest (x = 40 μm; y = 40 μm; and z = 10 μm) were randomly chosen, and volume of the elements of interest was calculated, summed and expressed as volume μm À3 (n = 200).
RT-PCR analysis of gene expression
The midbrain was dissected, and RNA was isolated using RNeasy Plus Universal Mini Kit (Qiagen, Ambion Inc., Austin, TX, USA) according to the manufacturer's instructions. MIQE guidelines were followed for RT-PCR analysis. RNA (2 μg) was reverse transcribed and real-time PCR for Tnf, and Mrc1 was performed in a 7300 Real-Time PCR System (Life Technologies, Monza, Italy). The amplification mixture contained 20 ng of cDNA, 10 μL 2× TaqManGene Expression PCR Master mix (Life Technologies, Monza, Italy) and 1 μL of specific 20× TaqMan Gene Expression Assay (Mm00485148-m1 for Mrc1/CD206 and Mm00443258-m1/ Tnf) (Pisanu et al., 2014) . Samples were analysed in triplicate with β-actin as housekeeping control (Pisanu et al., 2014) . Relative gene expression was calculated according to the 2-ΔΔCT method using the vehicle-treated tissue as control.
Beam traverse test
This test was used to assess motor performance of mice and to investigate whether MDG548 rescued MPTP-induced motor impairment (Schintu et al., 2009a) . The beam was constructed as described (Schintu et al., 2009a) . Mice were trained for two consecutive days to traverse the beam. On the test day, a grid (1 cm 2 ) of corresponding width was placed 1 cm above the beam, and mice were videotaped while traversing it for a total of five trials. Limb slips were considered errors, and total errors were calculated by an operator blinded to experimental groups (Schintu et al., 2009b) .
Data and statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018 ; Sigma-Aldrich) was dissolved in water. DMSO was added to vehicle and LPS-treated wells instead of MDG548. The final concentration of DMSO in culture medium was 0.1% for all experimental groups.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b,c) .
Results
MDG548 stimulated phagocytosis in MMGT12 microglia
We investigated the effect of MDG548 on phagocytosis in a functional beads-based assay and neuronal cells-based assay, in murine microglial cells MMGT12. We exposed the cells to the drug in the presence and absence of LPS for 24 h and then assessed their ability to engulf fluorescent latex microspheres ( Figure 1A ) or necrotic SH-SY5Y and cell debris ( Figure 1C) , by co-incubation and subsequent flow cytometry analysis. Control cells showed a basal level of phagocytosis ranging from 0.5% in the SH-SY5Y ( Figure 1D ) assay to 6% in the beads assay ( Figure 1B) , which was unaffected by LPS alone ( Figure 1A, B) . Phagocytosis was significantly increased by MDG548 alone, at both tested doses, as compared with controls. Moreover, MDG548 added 2 h after adding LPS within 24 h incubation time (LPS + MDG10s) further increased the percentage of phagocytotic cells, while MDG548 applied at the same time with LPS was less PPARγ and microglial phagocytosis in PD effective in driving microglia phagocytosis ( Figure 1B, D) , as shown in Figure 2 .
MDG548 altered microglia phenotype in LPS-stimulated MMGT12 microglia
We investigated the effect of MDG548 on proinflammatory and anti-inflammatory markers in MMGT12 cells. MDG548 displayed a dose-dependent and opposite effect on MRC1 and TNF-α levels. ELISA assay showed that 10 μM, but not 50 μM, of MDG548 significantly increased MRC1 levels and decreased TNF-α levels in unstimulated cells, as compared with vehicle (control) (Figure 2A ).
Ym1 and IL-10 were unaffected by MDG548, while IL-1β levels were in the low physiological range and therefore undetectable (data not shown). When cells were stimulated with LPS, MRC1 and IL-10 decreased below vehicle levels, while the secretion of TNF-α and IL-1β markedly increased above vehicle (compare absolute values of control in Figure 2A with Figure 2B , C, E, F). Again, Ym1 was unaffected ( Figure 2D ). Finally, when MDG548 10 μM was added 2 h after LPS (LPS + MDG10s), it reversed the LPS-induced decrease of MRC1 to control levels and attenuated the LPS-induced increase of TNF-α ( Figure 2B, E) . Moreover, IL-10 showed a tendency to increase after LPS + MDG10s (Figure 2C ), while IL-1β and Ym1 were
Figure 2 unaffected ( Figure 2D, F) . The same changes were not observed when MDG548 was applied at the same time as LPS. We also measured the iNOS IR in cells and found that LPS significantly increased the number of iNOS positive cells as compared with vehicle, while LPS + MDG10s totally reversed such effect ( Figure 2G ).
MDG548 increased the expression of CD68 and Beclin-1
In order to further investigate MDG548 effect on phagocytic activity, we analysed the expression of CD68, a scavenger receptor suggested to be involved in macrophage and microglial phagocytosis, by evaluating immunoreactivity for CD68 (CD68IR) in MMGT12 cells treated as in Table 1 ( Figure 3) . A preliminary experiment assessing the expression of PPARγ in MMGT12 cells showed constitutive expression in all cells. We therefore analysed CD68 IR colocalization in PPARγ-stained cells. LPS and MDG548 alone did not change CD68 IR, while MDG548 (10 μM) added after LPS strongly enhanced CD68 IR ( Figure 3A) . Again, the effect was limited to the experiment where MDG548 was administered 2 h after LPS, as adding MDG548 concomitantly with LPS did not affect CD68 levels. In search of a possible molecular mechanism of PPARγ-mediated effect on phagocytosis, we also investigated the expression of Beclin-1/BECN1. Beclin-1 plays an important role in both autophagy and phagocytosis in different cell types, including microglia (Lucin et al., 2013) . MMGT12 cells were treated as described in Table 1 , and we assessed Beclin-1 levels by Western blotting. We observed a marked increase of Beclin-1 expression in response to MDG548, no matter if it was applied alone or together with LPS. This increase was statistically significant for all MDG548-treated samples, except for LPS + MDG10c treatment (Figure 3C, D) . This indicated that Beclin-1 expression was regulated by PPARγ and may play a role in MDG548-induced phagocytosis.
MDG548 arrested nigral degeneration and motor impairment in MPTPp-treated mice
Next, we addressed the ability of MDG548 to arrest the MPTPinduced nigral degeneration and motor impairment in the MPTPp mouse model of PD, which is a widely used and validated model of progressive PD (Schintu et al., 2009b) . In accordance with previous reports (Schintu et al., 2009b) D), while the simultaneous administration of the PPARγ antagonist GW9662 (group MPTP + MDG548 + GW9662) attenuated the effect of MDG548, suggesting a PPARγ-mediated mechanism of neuroprotection ( Figure 4A, D) . The analysis of Nissl staining confirmed the MPTPp-induced cell loss and the protection by MDG548 (number of stained cells for vehicle: 16 238.4 ± 517.74; MPTP10: 8586.00 ± 884.27; and MPTP + MDG548: 13 508.00 ± 499.01). Moreover, the chronic administration of MPTPp caused a progressive motor impairment, as revealed by the increase of stepping errors measured by the beam walking test, as previously reported ( Figure 4E ) (Schintu et al., 2009b) . Daily MDG548 administration starting from the 24th day of MPTPp treatment fully reversed MPTPp-induced motor impairment, providing functional validation of neuroprotection and suggesting a disease-modifying effect of PPARγ stimulation. Consistent with these findings, the effects of MDG548 were blocked by co-administration of PPARγ antagonist GW9662 ( Figure 4E ).
MDG548 attenuated MPTPp-induced microgliosis in the SNc
The chronic MPTPp treatment induced a gradual increase of microgliosis, as indicated by the increase of the total area occupied by CD11b IR in the analysed region ( Figure 4B, F) . Moreover, cells displayed changes in cell morphology after the MPTPp treatment, as indicated by measurement of the mean area, obtained by outlining the body and primary processes for each cell ( Figure 4C , G). Morphology switched from a shape with a small body and highly ramified processes to an amoeboid form, in accordance with previous studies (Schintu et al., 2009b) . MDG548 attenuated the changes induced by MPTPp in cell proliferation as well as in cell morphology, while GW9662 counteracted the effect of MDG548 (Figures 4B and 5F , G).
MDG548 reversed the MPTPp-induced changes in MRC1 and cytokines in microglia
We performed confocal analysis of MRC1 IR and cytokines colocalized with CD11b in the SNc. The analysis showed that chronic MPTPp decreased MRC1 and TGF-β IR in CD11b-positive cells of the SNc, while increased TNF-α and IL-1β IR (Figures 5-7) . The co-administration of MDG548 with MPTPp enhanced the levels of MRC1 and TGF-β colocalized with CD11b, restoring them to physiological values, and reduced levels of TNF-α and IL-1β IR (Figures 5-7) , while GW9662 attenuated these effects of MDG548. Analysis of Mrc1 mRNA showed a decrease after MPTP10 treatment, compared with vehicle, which was restored by MPTP + MDG548 (Table 2 ). In addition, expression of Tnf mRNA did not change after MPTP10 or MPTP + MDG548, suggesting that the chronic exposure to MPTPp might induce a self-repression of TNF-α expression (Table 2) .
Discussion
The neuroprotective and disease-modifying potential of PPARγ agonists in PD and in other neurodegenerative pathologies has been widely reported, though the underlying mechanism is still debated (Mandrekar-Colucci and Landreth, 2011; Carta, 2013) . Here, we show that the PPARγ agonist MDG548 stimulated microglia phagocytic activity and modulated the profile of cytokines expression leading an alternative activation state in microglia, while suppressing inflammatory responses. These effects were observed in vitro in cultures of the microglial cell line MMGT12 as well as in vivo in a model of progressive PD, where MDG548 also displayed a disease-modifying activity, arresting the nigral dopaminergic degeneration. Several studies have demonstrated the pivotal role of PPARγ in peripheral macrophage/monocytes polarization and have shown that PPARγ is required for maturation of alternatively activated macrophages in physiological as well as pathological conditions (Odegaard and Chawla, 2011 ). Our results demonstrate that PPARγ exerted a similar function in microglia in an experimental model of PD and suggest that promoting phagocytosis together with the production of anti-inflammatory cytokines and suppression of pro-inflammatory molecules may underlie PPARγ-mediated neuroprotection in PD. Our results are compatible with earlier studies showing that PPARγ stimulation boosted the M2-like microglia phenotype and accelerated functional recovery in rodent models of cerebral haemorrhage or stroke (Zhao et al., 2015; Flores et al., 2016) and promoted phagocytosis in a model of Alzheimer's disease (Yamanaka et al., 2012; Savage et al., 2015) . The role of microglial phagocytosis in PD, whether beneficial or detrimental, is debated. Although some studies have proposed an increased phagocytic activity in microglia (Croisier et al., 2005; Theodore et al., 2008; Sanchez-Guajardo et al., 2010; Doorn et al., 2014; Fourgeaud et al., 2016) , others have reported a defective phagocytosis in this cell type or in other immune cells (Salman et al., 1999; Gardai et al., 2013) . Moreover, an increasing number of studies indicate that microglia contribute to the progression of neurodegeneration in PD, by acquiring an unremitting pro-inflammatory phenotype, with chronic production of pro-inflammatory cytokines, iNOS, ROS and reactive nitrogen species (Boka et al., 1994; Joers et al., 2017; López González et al., 2016; Mogi et al., 2007; Pisanu et al., 2014; Sawada et al., 2006) . The present study points to a reduced phagocytic activity by microglia in the MPTPp progressive model of PD, by showing a decreased MRC1 IR in these cells, which was associated with increased production of inflammatory cytokines.
To specifically address PPARγ stimulation in relation to microglial function, we first investigated the direct effect of MDG548 on cultured MMGT12 microglia, where the expression of PPARγ was first confirmed immunohistochemically, as shown in Figure 3 . Although limitations of the in vitro model used here must be taken into consideration, these results provided evidence for the direct effect of PPARγ stimulation on microglial cells, which cannot be determined in vivo, where the diffuse PPARγ expression in different cell types does not allow the determination of their function in a selected cell population. We measured the microglia phagocytic activity by two functional assays, which measured engulfment of latex beads or necrotic cells. Thereafter, we assessed MDG548 effect in a classical inflammatory model such as LPS stimulation, by analysing both typical markers of pro-inflammatory profile, such as TNF-α, IL-1β and iNOS, as well as molecules typically expressed by alternatively activated macrophages, such as IL-10, MRC1 and Ym1 (Croasdell et al., 2015) . In addition, we measured the expression of scavenger receptor CD68. Finally, we addressed a possible modulation of Beclin-1, a recently identified regulator of phagocytosis (Lucin et al., 2013) .
We observed that PPARγ stimulation with MDG548 induced a significant induction of phagocytosis of necrotic cells in untreated microglia and slightly increased the phagocytosis of latex beads. This was associated with a decrease of TNF-α release and a robust increase of MRC1 and Beclin-1 expression, suggesting that PPARγ stimulation itself induced a phagocytic microglia profile while lessening the production of inflammatory mediators. In particular, cytokine production was down-regulated by 10 μM MDG548 but not 50 μM, which instead significantly increased iNOS IR. In a previous study, we found that 10 μM MDG548 was neuroprotective, while 50 μM was cytotoxic to neurons, suggesting that additional intracellular pathways may be activated by such higher concentrations (Lecca et al., 2015) . Interestingly, LPS-stimulated MMGT12 microglia did not show any phagocytic activity or changes in Beclin-1 expression, while PPARγ and microglial phagocytosis in PD displayed increased levels of TNF-α, IL-1β and iNOS with a great suppression of MRC1, suggesting that LPS induced a pro-inflammatory phenotype with impaired phagocytic activity. When MDG548 was administered to LPS-stimulated microglia, we observed an amplified effect on phagocytosis as compared with LPS alone-treated cells and an increase of CD68. Previous studies have demonstrated the PPARγ-dependent regulation of CD68 expression in peripheral macrophages (Odegaard et al., 2007) . Moreover, MDG548 reversed the LPS-induced changes in cytokines and iNOS production. Remarkably, MDG548 was ineffective when added concurrently with LPS in all the assays performed in the present study. Although the investigation of mechanisms behind this finding goes beyond the scope of the present study, it should be pointed out that MDG548 might affect two main mechanisms of PPARγ-mediated control of microglia activation. PPARγ inhibits the expression of inflammatory genes via the interaction at multiple steps with the LPSactivated NF-κB pathway, including a direct protein-protein interaction with NF-κB (Varga et al., 2011) . This mechanism may be more efficient after LPS-induced release of NF-κB from NF-κB-IκB inactive complex. Moreover, PPARγ stimulates M2 polarization in macrophages through a crosstalk with the transcription factor STAT6 in its active phosphorylated state (Szanto et al., 2010) . Recent studies have demonstrated that NF-κB activation also induces an intracellular pathway for resolution of inflammation and M2 polarization of macrophages (Porta et al., 2009; Tugal et al., 2013) . Therefore, the previous activation of M1-related programs by LPS in microglia may paradoxically potentiate the effect of a subsequently administered PPARγ agonist. Our finding is of particular relevance for PD, where disease-modifying drugs are expected to change a pre-existing inflammatory environment. MDG548 significantly induced Beclin-1 levels; however, this effect was independent from LPS administration in contrast to the observations on phagocytosis and CD68 expression. As Beclin-1 plays also a role in autophagy regulation and it is induced when autophagy is stimulated (Janda et al., 2015) , Beclin-1 up-regulation by MDG548 may reflect a proautophagic capacity of this compound. Such an additional pharmacological activity of MDG548 would be beneficial, considering that autophagy has become a potential therapeutic target in PD (Janda et al., 2012; Janda et al., 2015; PlazaZabala et al., 2017) .
In vitro findings supported the observations made in the in vivo PD model, where the PPARγ agonist administered in the late stages of the disease was able to switch the MPTPpinduced phenotype of activated microglia and arrested the ongoing neurodegeneration. After chronic MPTPp treatment, microglia acquired a pro-inflammatory profile, as indicated by the increases of TNF-α and IL-1β and the decreases of MRC1 and TGF-β (Figure 8 ). MDG548 was administered in the late disease phase to investigate its disease-modifying potential. Following PPARγ stimulation, we observed a switch in the profile and function of microglia, which acquired a phenotype with high levels of MRC1 and TGF-β and low TNF-α and IL-1β, suggesting the acquisition of an 'alternative' activation state with increased phagocytic activity (Figure 8 ). The lack of modification of Tnf mRNA suggests that chronic exposure to MPTP might induce a feedback self-repression of gene expression at the analysed time point related to protein overproduction, in line with previous findings (Pisanu et al., 2014) . Our results also showed that MDG548 was neuroprotective as it arrested the MPTP-induced loss of SNc neurons and rescued the motor impairment, confirming a PPARγ-mediated protective effect in a PD model. Previous studies have reported TZD-induced changes of microglial response in terms of cytokines and iNOS production, both in rodent and primate models of PD, as well as a neuroprotective action of these drugs and MDG548 itself in PD models (Kitamura et al., 1999; Cunard et al., 2002; Ji et al., 2010; Carta et MDG548 restored TGF-β and IL-1β IR in microglia of MPTPp-treated mice. The percentage of colocalization of TGF-β and IL-1β in CD11b-positive cells was calculated in the most representative experimental groups vehicle, MPTP10 and MPTP + MDG548 (n = 5 for each experimental group). *P < 0.05, significantly different from vehicle;^P < 0.05, significantly different from MPTP10. Table 2 Analysis of Mrc1 and Tnf mRNA expression in the mouse midbrain et al., 2015). Interestingly, MDG548 was effective at a dose fivefold lower than TZDs, due to higher receptor affinity and BBB permeability (Dehmer et al., 2004; Schintu et al., 2009a; Nevin et al., 2012) . The use of TZDs has recently encountered several safety concerns, which largely limit their translation to the clinic in PD (Carta and Simuni, 2015; Simon et al., 2015) . Particularly, as TZDs were originally developed for the treatment of type 2 diabetes, their pharmacokinetic features limit CNS entrance, requiring elevated dosage in neurological disorders.
In conclusion, numerous studies indicate that microglia are subjected to many plastic changes of their phenotype both in physiological and pathological conditions, and targeting the microglial phenotype is a recognized potential therapeutic target in neurological disorders. The present study suggests that boosting the phagocytic function of microglia and the acquisition of an anti-inflammatory phenotype may represent a novel mechanism of PPARγ-mediated neuroprotection (Figure 8 ). Despite the discouraging results recently provided by clinical trials in PD patients with the TZD pioglitazone, our study adds to an increasing literature providing the rationale to pursue clinical investigation of PPARγ in neurodegenerative diseases.
Figure 8
Diagram summarizing the observed effects and suggested mechanism of PPAR-γ-mediated neuroprotection in the MPTPp model of PD. Damaged dopaminergic (DA) neurons activate microglia to assume a M1-like pro-inflammatory phenotype with increased release of inflammatory molecules and defective phagocytosis. Administration of the PPAR-γ agonist boosts phagocytosis and stimulates microglia to acquire an anti-inflammatory phenotype, therefore resulting in both rescuing and scavenging activity.
